Kinfo
FibroBiologics, Inc. logo

FibroBiologics, Inc.

FBLGNASDAQHealthcare·US · USD
$0.96
-0.01 (-1.24%)
Prices as of November 5, 2026 · market closed

Price

Key statistics

Valuation
Market cap6.78M USD
Enterprise value4.54M USD
Trailing P/E-0.11
Forward P/E-0.29
PEG ratio0.00
Price / sales0.00
Price / book1.23
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-95.77%
Return on equity-660.08%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-16.47M USD
Net income-18.14M USD
Diluted EPS-$5.01
Rev. growth (YoY)0.00%
Balance sheet
Total cash3.52M USD
Total debt1.46M USD
Debt / equity31.54
Current ratio2.64
Book value / share$0.76
Cash flow (TTM)
Operating cash flow-14.79M USD
Levered free cash flow-8.37M USD
Shares & price
Shares outstanding6.08M
Float5.19M
Held by institutions15.25%
Beta1.84
50-day MA$1.29
200-day MA$2.32
52-week high$9.60
52-week low$0.62
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-07-31-0.93-0.66+29.03%2026-07-17-0.09-0.14−55.56%2026-04-30-1.35-1.33+1.48%2026-04-080.350.57+62.86%
About FibroBiologics, Inc.

FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing fibroblast-based therapies for chronic diseases. Its current programs center on regenerative medicine and cell therapy applications for conditions such as wound healing, multiple sclerosis, degenerative disc disease, psoriasis, and certain cancers. The company’s pipeline includes product candidates such as CYWC628, CYMS101, CYPS317, and CybroCell, which are being developed to address areas of significant unmet medical need. FibroBiologics also works with fibroblast cells and fibroblast-derived materials in research programs related to tissue regeneration and immune modulation. Based in Houston, Texas, FibroBiologics plays a specialized role in the biotechnology market by advancing cell-based approaches designed for therapeutic use across several disease areas.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Peter O'Heeron
Employees
13
Headquarters
Houston, TX, United States

Frequently asked questions about FibroBiologics, Inc.